Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Disease or Syndrome > Steatohepatitis

Steatohepatitis

Steatohepatitis is a form of liver disease characterized by the accumulation of fat in the liver, accompanied by inflammation and injury to liver cells.
This condition can progress to more severe forms of liver disease, such as cirrhosis and liver failure, if left untreated.
Steatohepatitis can be caused by a variety of factors, including excessive alcohol consumption, obesity, and certain metabolic disorders.
Symptoms may include fatigue, abdominal pain, and yellowing of the skin and eyes.
Early detection and appropriate treatment are crucial for managing steatohepatitis and preventing further liver damage.
Researchers and clinicians can leverage the power of PubCompare.ai to optimize their steatohepatitis studies and drive breakthroughs in this important area of liver health.

Most cited protocols related to «Steatohepatitis»

1
Standardized Blinded Review of NASH Biopsies
Biopsies from adult patients enrolled in either the Database study or pretreatment biopsies from the adult treatment trial (Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with NASH) (PIVENS) were reviewed in a standardized blinded fashion by the Pathology Committee of the NASH CRN, composed of a pathologist from each of the 8 clinical centers, and one from the National Cancer Institute. Assignment of a diagnostic category was based on consensus recognition of the distinctive features of SH independent of the degree of NAFLD severity as indicated by the NAS. Biopsies that had been classified by the Pathology Committee during Central Review as “cirrhosis with or without features of NAFLD or NASH” were excluded from this analysis, as it is well recognized that the active lesions of steatohepatitis may not be retained in cirrhosis. Biopsies with the zone 1 borderline pattern were also excluded as this is a pattern that most commonly occurs in pediatric NAFLD and was rare among our adult cases. When more than one biopsy for a subject was available, only the first biopsy was used in the analysis. Histologic and clinical data were analyzed as described below.
Brunt E.M., Kleiner D.E., Wilson L.A., Belt P, & Neuschwander-Tetri B.A. (2011). The NAS and The Histopathologic Diagnosis in NAFLD: Distinct Clinicopathologic Meanings. Hepatology (Baltimore, Md.), 53(3), 810-820.
Publication 2010
Adult Biopsy Cirrhosis Diagnosis Non-alcoholic Fatty Liver Disease Nonalcoholic Steatohepatitis Pathologists Patients Pioglitazone Placebos Steatohepatitis Vitamin E
2
Optimized Fibrosis Scoring for Older NAFLD Patients
This study included consecutive patients with biopsy-proven NAFLD who attended specialist fatty liver clinics at the Freeman Hospital, Newcastle upon Tyne, UK; Addenbrooke's Hospital, Cambridge, UK; Antwerp University Hospital, Edegem, Belgium; and Pitié-Salpêtrière Hospital, Paris, France. These formed the initial ascertainment cohort. Liver biopsies were conducted as per routine clinical care for the investigation of abnormal liver function tests (raised ALT, AST, or gamma-glutamyl transferase) or to stage disease severity in patients with radiological evidence of fatty liver. Clinical and laboratory data were collected prospectively from the time of liver biopsy. Patients with evidence of other liver disease (autoimmune hepatitis, viral hepatitis, drug induced liver injury, hemochromatosis, cholestatic liver disease, or Wilson's disease) were excluded. In addition, subjects consuming excessive amounts of alcohol (alcohol intake >20 g/day for women; >30 g/day for men) at the time of biopsy or in the past were excluded. Patients with incomplete data to calculate all the non-invasive scores were excluded.
Relevant clinical details, including gender, age, weight, and height, were obtained at the time of biopsy. The body mass index was calculated by the formula: weight (kg)/height (m)2. Patients were identified as having diabetes if they had been diagnosed with diabetes according to the 2004 American Diabetes Association criteria or if they were taking an oral hypoglycemic drug or insulin (23 (link)).
Percutaneous liver biopsies were performed as per unit protocol at the sites and were assessed by an experienced local hepatopathologist. Patients with liver biopsies specimens <15 mm in length were excluded. Histological scoring was performed according to the non-alcoholic steatohepatitis (NASH) Clinical Research Network criteria (24 (link)). The NAFLD activity score was graded from 0 to 8, including scores for steatosis (0–3), lobular inflammation (0–3), and hepatocellular ballooning (0–2). NASH was defined as steatosis with hepatocyte ballooning and inflammation ± fibrosis (25 (link)). Fibrosis was staged from F0 to F4 (24 (link)). Patients with stage F3 or F4 fibrosis were considered to have advanced fibrosis.
The AST/ALT ratio, FIB-4, and NFS were calculated from blood tests taken at the time of liver biopsy as previously described (16 (link), 26 (link), 27 (link)). Details of the formulas and cutoffs for the tests under investigation are shown in Table 1. Previously published cutoffs were used to exclude and diagnose advanced fibrosis for each score (15 (link), 16 (link), 18 (link), 19 (link))
To validate new cutoffs for the NFS and FIB-4 score optimized for use in older patients (aged ≥65 years) that were derived in the initial ascertainment cohort, anonymized biochemical, histological, and anthropometric data were collected from a separate group of histologically characterized patients from the EPoS/EASL European NAFLD Registry. The “European NAFLD Registry” was established during the EU FP7 FLIP project (2010-) and is now maintained by the EU H2020 EPoS (Elucidating Pathways of Steatohepatitis) consortium to facilitate collaborative research into NAFLD. It is the largest multi-national registry of patients with histologically characterized NAFLD. These patients had data collected according to the same methodology as the main cohort.
All statistical analyses were performed using the SPSS software version 22.0 (SPSS, Chicago, IL). Continuous normally distributed variables were represented as mean ± s.d. Categorical and non-normal variables were summarized as median and range. Chi squared tests were used to determine the distribution of categorical variables between groups. To compare the means of normally distributed variables between groups, the Student's t-test or analysis of variance test was performed. To determine differences between groups for continuous non-normally distributed variables, medians were compared using the Mann–Whitney U-test. The diagnostic performance of the non-invasive tests was assessed by receiver operating characteristic (ROC) curve analysis. The area under the ROC (AUROC) was used as an index to compare the accuracy of tests. The sensitivity, specificity, positive predictive values (PPVs), negative predictive values (NPVs), positive likelihood ratios (LR +ve), and negative likelihood ratios (LR −ve) for relevant cutoffs were also displayed. In order to assess changes in sensitivity and specificity of the tests with age, plots of sensitivity and specificity in different age groups were displayed graphically. New cutoffs for the FIB-4 and NFS were derived for ≥65-year-old patients by taking the point on the ROC where the combined value of sensitivity and specificity was the highest. As the prevalence of advanced fibrosis can vary in different populations, the PPVs and NPVs for the new cutoffs were displayed at advanced fibrosis prevalence rates of 5, 10, 20, 30, and 40%. A P value of <0.05 was considered significant.
McPherson S., Hardy T., Dufour J.F., Petta S., Romero-Gomez M., Allison M., Oliveira C.P., Francque S., Van Gaal L., Schattenberg J.M., Tiniakos D., Burt A., Bugianesi E., Ratziu V., Day C.P, & Anstee Q.M. (2016). Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. The American Journal of Gastroenterology, 112(5), 740-751.
Publication 2016
Age Groups Autoimmune Chronic Hepatitis Biopsy Cholestasis Diabetes Mellitus Diagnosis Diet, Formula Drug-Induced Liver Disease Erythropoietin Ethanol Europeans Fatty Liver Fibrosis gamma-Glutamyl Transpeptidase Gender Hematologic Tests Hemochromatosis Hepatitis Viruses Hepatocyte Hepatolenticular Degeneration Hypersensitivity Hypoglycemic Agents Index, Body Mass Inflammation Insulin Liver Liver Diseases Liver Function Tests Non-alcoholic Fatty Liver Disease Nonalcoholic Steatohepatitis Patients Population Group Specialists Steatohepatitis Tests, Diagnostic Woman X-Rays, Diagnostic
3
Histologic Evaluation of Steatohepatitis
The following histologic data were analyzed: diagnosis rendered by the Pathology Committee (i.e. “not steatohepatitis”, “borderline, zone 3 pattern”, “definite steatohepatitis”); the aggregate NAS; the score of each component of the NAS (steatosis (0–3), lobular inflammation (0–3), ballooning (0–2)), and fibrosis scores (0,1a,1b,1c,2,3). In addition, portal chronic inflammation and steatosis location were included. The "borderline zone 3 pattern" was reserved for biopsies that have zone 3 accentuation of lesions, but not all the lesions for definite steatohepatitis were present. This definition is purposely left broad so as to neither preclude further evaluation nor include the biopsies in the "not SH" category.
Brunt E.M., Kleiner D.E., Wilson L.A., Belt P, & Neuschwander-Tetri B.A. (2011). The NAS and The Histopathologic Diagnosis in NAFLD: Distinct Clinicopathologic Meanings. Hepatology (Baltimore, Md.), 53(3), 810-820.
Publication 2010
Biopsy Diagnosis Fibrosis Inflammation Steatohepatitis
4
Standardized Rodent NASH Histological Scoring
Briefly, the two key features of NASH, steatosis and inflammation, were categorized as follows: steatosis was determined by analyzing hepatocellular vesicular steatosis, i.e. macrovesicular steatosis and microvesicular steatosis separately, and by hepatocellular hypertrophy as defined below (Fig. 2). Inflammation was scored by analyzing the amount of inflammatory cell aggregates (Fig. 2). The proposed rodent scoring system is shown in Table 4 and options for its use in diagnosis are shown in S1 Fig. The purpose of this scoring system is however not to derive a single score, but to score the individual features.
Macrovesicular steatosis and microvesicular steatosis were both separately scored and the severity was graded, based on the percentage of the total area affected, into the following categories: 0 (<5%), 1 (5–33%), 2 (34–66%) and 3 (>66%). The difference between macrovesicular and microvesicular steatosis was defined by whether the vacuoles displaced the nucleus to the side (macrovesicular) or not (microvesicular). Similarly, the level of hepatocellular hypertrophy, defined as cellular enlargement more than 1.5 times the normal hepatocyte diameter, was scored, based on the percentage of the total area affected, into the following categories: 0 (<5%), 1 (5–33%), 2 (34–66%) and 3 (>66%). For hepatocellular hypertrophy the evaluation was merely based on abnormal enlargement of the cells, irrespective of rounding of the cells and/or changes in cytoplasm or the number of vacuoles, and is therefore not a substitute of ballooning. The unweight sum of the scores for steatosis (macrovesicular steatosis, microvesicular steatosis and hypertrophy) thus ranged from 0–9. Both steatosis and hypertrophy were evaluated at a 40 to 100× magnification and only the sheets of hepatocytes were taken into account (terminal hepatic venules and portal tracts etc were excluded).
Inflammation was evaluated by counting the number of inflammatory foci per field using a 100 x magnification (view size of 3.1 mm2). A focus was defined a cluster, not a row, of ≥5 inflammatory cells. Five different fields were counted and the average was subsequently scored into the following categories: normal (<0.5 foci), slight (0.5–1.0 foci), moderate (1.0–2.0 foci), severe (>2.0 foci).
Hepatic fibrosis was identified using Sirius Red stained slides at 40 x magnification and evaluated by scoring whether pathologic collagen staining was absent (only in vessels) or collagen staining observed within the liver slide, the latter further defined as mild, moderate or massive. In addition, the percentage of the total area affected was evaluated using using image analysis of surface area on Sirius red stained slides.
Liang W., Menke A.L., Driessen A., Koek G.H., Lindeman J.H., Stoop R., Havekes L.M., Kleemann R, & van den Hoek A.M. (2014). Establishment of a General NAFLD Scoring System for Rodent Models and Comparison to Human Liver Pathology. PLoS ONE, 9(12), e115922.
Full text: Click here
Publication 2014
Blood Vessel Cell-Derived Microparticles Cell Enlargement Cell Nucleus Cells Collagen Cytoplasm Diagnosis Fibrosis, Liver Hepatocyte Hypertrophy Inflammation Liver Nonalcoholic Steatohepatitis Portal System Rodent Steatohepatitis Vacuole Venules
5
Diagnostic Accuracy of Ultrasound in Fatty Liver
Three investigators (R.H., M.L., and S.B.) independently reviewed the search results to determine article inclusion and perform data abstraction. Discrepancies were resolved by consensus. For each selected publication, we abstracted year of publication, country, inclusion criteria, histological definition of fatty liver (i.e., simple steatosis and steatohepatitis), number of participants undergoing ultrasound and comparison tests (if applicable), definitions of fatty liver used in the study, ultra-sonographic parameters evaluated, and reported measures of accuracy and reliability. For articles with no reported measure of accuracy, we estimated the sensitivity and specificity from the available data. We evaluated the quality of each article by applying modified Quality Assessment of Diagnostic Accuracy Studies (QUADAS)12 (link) and STAndards for the Reporting of Diagnostic accuracy studies (STARD) criteria.13 (link)Study outcome was the presence of fatty liver as a dichotomous variable, using the specific criteria and definitions used in each study. For ultrasound, a few studies reported four categories, and we combined the normal/mild categories as absence of fatty liver, and the moderate/severe categories as presence of fatty liver. For histology, we used the presence of greater than or equal to 20%-30% fat infiltration to define fatty liver, except for Nagata et al. (≥10%), Guajardo-Salinas (>0%), and Soresi (>5%). We conducted secondary analyses on the diagnostic accuracy using lower levels of fat infiltration on histology as diagnostic criteria (i.e., <5%, ≥10%, and a ≥20%-30%).
Because number of ultrasonographic parameters have been used alone or in combination to diagnose fatty liver; if data were available, we evaluated the diagnostic accuracy of the following parameters: (1) parenchymal brightness, (2) liver-to-kidney contrast, (3) deep beam attenuation, (4) bright vessel walls, and (5) gallbladder wall definition. Given that some studies reported or combined different histological findings, such as inflammation and fibrosis, we performed secondary analyses to study how accurate ultrasound was in identifying fatty infiltration with or without inflammation or fibrosis.
Hernaez R., Lazo M., Bonekamp S., Kamel I., Brancati F.L., Guallar E, & Clark J.M. (2011). Diagnostic Accuracy and Reliability of Ultrasonography for the Detection of Fatty Liver: A Meta-Analysis. Hepatology (Baltimore, Md.), 54(3), 1082-1090.
Publication 2011
Blood Vessel Diagnosis Fatty Liver Fibrosis Gallbladder Inflammation Kidney Liver Steatohepatitis Tests, Diagnostic Ultrasonography

Most recents protocols related to «Steatohepatitis»

1
Statistical Analysis of Steatosis Grades
Data were analyzed using the Statistical Package for Social Sciences (SPSS) version 23.0 (SPSS Inc., IBM, Armonk, New York, United States). Test of normality of distribution was carried out using the Shapiro-Wilk test. The results were expressed as numbers and percentages (categorical variables) and as mean, standard deviation, and minimum and maximum for continuous variables. Measurement of the strength and direction of the relationship/correlation between two continuous and categorical variables in normally distributed data was performed using the Pearson correlation test and the chi-square (X2) test, respectively. An independent student t-test was performed to determine the difference between two means. One-way analysis of variance (ANOVA) with Tukey’s post hoc analysis was used to determine significant differences in the means of the laboratory results according to grades of steatosis. All p-values were two-tailed, and statistical significance was set at p < 0.05.
Alfadda A.A., Almaghamsi A.M., Sherbeeni S.M., Alqutub A.N., Aldosary A.S., Isnani A.C., Al-Daghri N., Taylor-Robinson S.D, & Gul R. (2023). Alterations in circulating lipidomic profile in patients with type 2 diabetes with or without non-alcoholic fatty liver disease. Frontiers in Molecular Biosciences, 10, 1030661.
Full text: Click here
Publication 2023
Steatohepatitis Student
2
Liver Steatosis and Fibrosis Evaluation with FibroScan
FibroScan® 502 and FibroScan® 530 Compact, with two probes - Medium (M+) and Extra-large (XL+) (Echosens Ltd., Paris, France) were used for measuring CAP—as surrogate measure of liver fat content, and liver stiffness measurement (LSM)—as a surrogate measure of hepatic fibrosis. The device estimates liver steatosis in decibel/meter (dB/m) and liver stiffness in kilopascal (kPa). CAP and LSM were obtained simultaneously in each examination. The type of probe required for each participant was selected by an automatic probe selection tool embedded within the FibroScan® operating software. A successful vibration controlled transient elastography (VCTE) exam was defined by the acquisition of ten successful measurements, where the interquartile range of the LSM did not exceed 30% of the median LSM. Therefore, an “uninterpretable” VCTE examination encompassed failures on one or both accounts. Each patient underwent VCTE examination after 3 h of fasting. All VCTE examinations were performed by two experienced physicians. The optimal cut-off values for classifying steatosis grades were as follows: S0 (CAP <248 dB/m), no steatosis; S1 (CAP 248 to <268 dB/m), mild steatosis; S2 (CAP 268 to <280 dB/m), moderate steatosis; and (S3 CAP ≥280 dB/m), severe steatosis (Karlas et al., 2017 (link)), and the optimal cut-off values for classifying fibrosis grades were: F0-F1 (<7.9 kPa), no fibrosis; F2 (7.9 to <8.8 kPa), moderate fibrosis; F3 (8.8 to <11.7 kPa), severe fibrosis; and F4 (≥11.7 kPa), liver cirrhosis (Abeysekera et al., 2020 (link)).
Alfadda A.A., Almaghamsi A.M., Sherbeeni S.M., Alqutub A.N., Aldosary A.S., Isnani A.C., Al-Daghri N., Taylor-Robinson S.D, & Gul R. (2023). Alterations in circulating lipidomic profile in patients with type 2 diabetes with or without non-alcoholic fatty liver disease. Frontiers in Molecular Biosciences, 10, 1030661.
Full text: Click here
Publication 2023
Elasticity Imaging Techniques Fatty Liver Fibrosis Fibrosis, Liver Liver Liver Cirrhosis Medical Devices Patients Physical Examination Physicians Steatohepatitis Transients Vibration
3
Diagnostic Criteria for Metabolic Syndrome
A Canon CR-2 Digital Retinal Camera was performed to obtain two-field fundus photography of patient’s eyes (Canon Inc., Kanagawa, Japan). The presence of DR was assessed by high-quality fundus photographs and an ophthalmologist. NAFLD diagnosis was based on the detection of hepatic steatosis by abdominal ultrasound while excluding drugs, viruses, or alcohol as the cause (40 (link)). MetS was defined according to Chinese Diabetes Society (CDS) criteria (41 (link)) if they have three or more of the following risk factors (1): overweight or obese (BMI ≥ 25.0 kg/m2) (2); hyperglycemia (FBG ≥ 6.1 mmol/l and/or 2-hour postprandial plasma glucose ≥ 7.8 mmol/l, or under treatment for diabetes) (3); hypertension (SBP ≥ 140 mmHg, DBP ≥ 90 mmHg, or on antihypertensive medication); and (4) dyslipidemia, defined as TG ≥ 1.7 mmol/l and/or HDL-C < 0.9 mmol/l (men) or <1.0 mmol/l (women). CHD was defined as a positive history of myocardial infarction, bypass operation, a diagnostic finding in angiography or positive exercise test (42 (link)).
Yan P., Wu Y., Dan X., Wu X., Tang Q., Chen X., Xu Y., Zhu J., Miao Y, & Wan Q. (2023). Aspartate aminotransferase/alanine aminotransferase ratio was associated with type 2 diabetic peripheral neuropathy in a Chinese population: A cross-sectional study. Frontiers in Endocrinology, 14, 1064125.
Full text: Click here
Publication 2023
Abdomen Angiography Antihypertensive Agents Chinese Diabetes Mellitus Diagnosis Dyslipidemias Ethanol Exercise Tests Fingers Fundus Oculi Glucose High Blood Pressures Hyperglycemia Myocardial Infarction Non-alcoholic Fatty Liver Disease Obesity Ophthalmologists Patients Pharmaceutical Preparations Plasma Retina Steatohepatitis Ultrasonics Virus Woman
4
Quantifying Murine Cardiovascular Pathology
Liver tissues were sectioned and stained to assess steatosis (Haemotoxylin and Eosin (H&E)) or fibrosis (picrosirius red). Immediately following cervical dislocation, hearts with attached aortic root were immersed in formalin and stored at 4 °C for 24 h, before being transferred to PBS until further analysis. Hearts were bisected to remove the lower ventricles, frozen in OCT and subsequently sectioned at 5 µm intervals until the aortic sinus was reached. Sections of aortic roots of comparable anatomical position were obtained by NHS Grampian pathology unit. A single section from each mouse (n = 4–5) was mounted and stained with oil red O to assess plaque formation. The descending aorta was prepared for en face staining. Briefly aortas were trimmed of perivascular adipose tissue, cut longitudinally, and stained with Sudan IV to assess plaque formation. Images were captured using a light microscope and plaque formation quantified using Image J software. Plaque formation in aortic root sections was total area measured, whereas for en face plaque staining was calculated as a percentage of the total surface area of the vessel.
Thompson D., Mahmood S., Morrice N., Kamli-Salino S., Dekeryte R., Hoffmann P.A., Doherty M.K., Whitfield P.D., Delibegović M, & Mody N. (2023). Fenretinide inhibits obesity and fatty liver disease but induces Smpd3 to increase serum ceramides and worsen atherosclerosis in LDLR−/− mice. Scientific Reports, 13, 3937.
Full text: Click here
Publication 2023
Aorta Aortic Root Blood Vessel Descending Aorta Eosin Face Fibrosis Formalin Freezing Heart Heart Ventricle Hematoxylin Joint Dislocations Light Microscopy Liver Mice, Laboratory Neck Scarlet Red Senile Plaques Sinus, Aortic Steatohepatitis Tissue, Adipose Tissues
5
Histological Assessment of NASH Liver Samples
Human paraffin-embedded liver tissues were obtained from the Department of Pathology at Peking University People’s Hospital. In this study, 6 liver tissue samples from biopsy-proven NASH patients with fibrosis and 3 samples from healthy donors (age ≥18 years) were eligible and included. Patients with viral hepatitis, alcoholic liver disease, drug-induced liver disease, autoimmune liver disease, cholestatic liver disease or hereditary metabolic liver disease were not ineligible. We did not assess whether subjects were male or female because sex was not the analysis object in this study. We did not check for sample sizes using a power analysis because our study does not report statistics on between groups or within group variables. Informed consent forms were obtained from all participants. This study was approved by the Ethics Committee of Peking University People’s Hospital (2022PHB088-001) and conformed to the ethical guidelines of the 1975 Declaration of Helsinki.
Each sample (human and mouse) was sectioned at a thickness of 4 μm for histological assessment and immunohistochemistry (IHC). Using hematoxylin and eosin (H&E) and Sirius Red (SR) staining, liver histology for all participants was evaluated by two specialized pathologists who were blinded to the patient and mouse details according to the NASH Clinical Research Network (NASH CRN) System (steatosis was scored from 0-3, ballooning: 0-2, lobular inflammation: 0-3, portal inflammation: 0-2, and liver fibrosis: 0 to 4).
Wang X., Wang Z., Liu B., Jin R., Song Y., Fei R., Cong X., Huang R., Li X., Yang J., Wei L., Rao H, & Liu F. (2023). Characteristic gene expression in the liver monocyte-macrophage-DC system is associated with the progression of fibrosis in NASH. Frontiers in Immunology, 14, 1098056.
Full text: Click here
Publication 2023
Alcoholic Liver Diseases Autoimmune Diseases Biopsy Cholestasis Donors Drug-Induced Liver Disease Eosin Ethics Committees, Clinical Fibrosis Fibrosis, Liver Hematoxylin Hepatitis Viruses Hepatobiliary Disorder Homo sapiens Immunohistochemistry Inflammation Liver Males Mus Nonalcoholic Steatohepatitis Paraffin Pathologists Patients Steatohepatitis Tissues Woman

Top products related to «Steatohepatitis»

1
Fibroscan by Echosens
Sourced in France, United States
FibroScan is a non-invasive diagnostic device that uses vibration-controlled transient elastography (VCTE) technology to measure liver stiffness. The device transmits a mild vibration through the skin and measures the velocity of the resulting shear wave, which is directly related to the stiffness of the liver tissue. This information can be used to assess the degree of liver fibrosis.
2
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
3
Oil red o by Merck Group
Sourced in United States, Germany, China, Japan, United Kingdom, Sao Tome and Principe, Italy, Macao, Australia, France, Switzerland, Spain, India, Poland, Canada
Oil Red O is a fat-soluble dye used in histology and cell biology for the staining of neutral lipids, such as triglycerides and cholesterol esters. It is a useful tool for the identification and visualization of lipid-rich structures in cells and tissues.
4
Fibroscan 502 touch by Echosens
Sourced in France
The FibroScan 502 Touch is a non-invasive diagnostic device designed to measure liver stiffness and controlled attenuation parameter (CAP). It uses vibration-controlled transient elastography (VCTE) technology to assess liver fibrosis and steatosis.
5
Palmitic acid by Merck Group
Sourced in United States, Germany, China, United Kingdom, Sao Tome and Principe, France, Italy, Macao, Canada, Japan, India, Australia, Panama, Ireland, Hungary, Switzerland
Palmitic acid is a saturated fatty acid with the chemical formula CH3(CH2)14COOH. It is a colorless, odorless solid at room temperature. Palmitic acid is a common constituent of animal and vegetable fats and oils.
6
Oleic acid by Merck Group
Sourced in United States, Germany, China, Italy, Japan, France, India, Spain, Sao Tome and Principe, United Kingdom, Sweden, Poland, Australia, Austria, Singapore, Canada, Switzerland, Ireland, Brazil, Saudi Arabia
Oleic acid is a long-chain monounsaturated fatty acid commonly used in various laboratory applications. It is a colorless to light-yellow liquid with a characteristic odor. Oleic acid is widely utilized as a component in various laboratory reagents and formulations, often serving as a surfactant or emulsifier.
7
Sas 9 by SAS Institute
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
8
Bovine serum albumin (bsa) by Merck Group
Sourced in United States, Germany, United Kingdom, China, Italy, Japan, France, Sao Tome and Principe, Canada, Macao, Spain, Switzerland, Australia, India, Israel, Belgium, Poland, Sweden, Denmark, Ireland, Hungary, Netherlands, Czechia, Brazil, Austria, Singapore, Portugal, Panama, Chile, Senegal, Morocco, Slovenia, New Zealand, Finland, Thailand, Uruguay, Argentina, Saudi Arabia, Romania, Greece, Mexico
Bovine serum albumin (BSA) is a common laboratory reagent derived from bovine blood plasma. It is a protein that serves as a stabilizer and blocking agent in various biochemical and immunological applications. BSA is widely used to maintain the activity and solubility of enzymes, proteins, and other biomolecules in experimental settings.
9
Dulbecco modified eagle medium (dmem) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, France, Australia, Canada, Japan, Italy, Switzerland, Belgium, Austria, Spain, Israel, New Zealand, Ireland, Denmark, India, Poland, Sweden, Argentina, Netherlands, Brazil, Macao, Singapore, Sao Tome and Principe, Cameroon, Hong Kong, Portugal, Morocco, Hungary, Finland, Puerto Rico, Holy See (Vatican City State), Gabon, Bulgaria, Norway, Jamaica
DMEM (Dulbecco's Modified Eagle's Medium) is a cell culture medium formulated to support the growth and maintenance of a variety of cell types, including mammalian cells. It provides essential nutrients, amino acids, vitamins, and other components necessary for cell proliferation and survival in an in vitro environment.

More about "Steatohepatitis"

Steatohepatitis is a form of nonalcoholic fatty liver disease (NAFLD) characterized by the accumulation of fat in the liver, accompanied by inflammation and injury to liver cells.
This condition, also known as nonalcoholic steatohepatitis (NASH), can progress to more severe forms of liver disease, such as cirrhosis and liver failure, if left untreated.
The causes of steatohepatitis can be varied, including excessive alcohol consumption, obesity, metabolic disorders like type 2 diabetes, and certain medications.
Symptoms may include fatigue, abdominal pain, and yellowing of the skin and eyes (jaundice).
Early detection and appropriate treatment are crucial for managing steatohepatitis and preventing further liver damage.
FibroScan, a non-invasive diagnostic tool, can be used to assess the degree of liver fibrosis in individuals with steatohepatitis.
Additionally, FBS (fasting blood sugar) and Oil Red O staining can help in the diagnosis and monitoring of this condition.
PubCompare.ai is a powerful tool that can help researchers and clinicians optimize their steatohepatitis studies.
By leveraging AI-driven protocol comparisons, researchers can easily locate and identify the best protocols and products from literature, pre-prints, and patents, improving reproducibility and accuracy in their studies.
Other relevant terms and technologies include FibroScan 502 Touch, which is a non-invasive device used to measure liver stiffness; Palmitic acid and Oleic acid, which are fatty acids associated with the development of steatohepatitis; SAS 9.4, a statistical software used in data analysis; and Bovine serum albumin, a common component in cell culture media like DMEM (Dulbero Modified Eagle Medium).